Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Disorder (US)
Bipolar disorder (BPD) is a chronic condition characterized by recurrent episodes of aberrant mood, with patients experiencing manic, depressive, or mixed symptoms between periods of stable mood. Bipolar mania is typically marked by elevated mood and heightened activity levels that significantly impair daily functioning, while bipolar depression commonly presents with fatigue, insomnia, suicidal thoughts, and feelings of worthlessness. Treatment is highly individualized based on symptom patterns and medication response, using agents such as lamotrigine, quetiapine, aripiprazole, antidepressants, or combination regimens. The market is highly genericized and price-conscious, posing a challenge for newer branded agents entering the market. This report uses national claims data to assess therapy use in newly diagnosed and recently treated BPD patients, providing insights into the current therapeutic landscape.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed BPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed BPD patients?
- How have AbbVie’s Vraylar and J&J’s Caplyta been integrated into the treatment algorithm, and what are their source of business?
- What percentage of BPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of BPD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drugtreated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
Geography: United States
Real-world data: U.S. pharmacy and medical claims data
Key drugs covered: Vraylar, Caplyta, Lybalvi, Latuda, lithium, lamotrigine, sertraline, quetiapine, aripiprazole, benzodiazepines
Key analyses:
- Brand / therapy usage across longitudinal patient sample
- Newly diagnosed patient analysis
- Treatment initiation and progression
- Line of therapy analysis
- Combination therapy analysis
- Source of business for recently treated patients
- Persistency and compliance analysis
- Product-level patient flow
